13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001615982
Total reported value
$3.3B
$3.3B
33 檔
45.5%
As reported in its official Q1 2026 Form 13F filing, Venrock Adviser, LLC's tracked investment portfolio stood at $3.3B with 33 total positions.
In Q1 2026, Venrock Adviser, LLC displayed an active expansion posture, initiating 8 new positions and adding to 6 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including APGE, ERAS, ORKA) accounted for 45.5% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics Inc | Stock-Other | 26.68% | +7.50% | — | |
| 2 | ERAS | Erasca Inc | Stock-Other | 9.89% | +0.05% | -8.26% | |
| 3 | ORKA | Oruka Therapeutics Inc | Stock-Other | 7.60% | +4.37% | — | |
| 4 | SYRE | Spyre Therapeutics Inc | Stock-Other | 6.94% | +1.10% | — | |
| 5 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 4.86% | -4.86% | EXIT | |
| 6 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 3.70% | -0.21% | +18.00% | |
| 7 | DMRA | Damora Therapeutics Inc | Stock-Other | 3.48% | -0.64% | — | |
| 8 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.27% | -0.19% | +41.44% | |
| 9 | COGT | Cogent Biosciences Inc | Stock-Other | 2.87% | -0.94% | — | |
| 10 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.83% | -1.02% | — | |
| 11 | SVRA | Savara Inc | Stock-Other | 2.80% | -0.05% | — | |
| 12 | ELVN | Enliven Therapeutics Inc | Stock-Other | 2.53% | -1.72% | -46.49% | |
| 13 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.04% | -0.62% | -23.90% | |
| 14 | VOR | Vor Biopharma Inc | Stock-Other | 2.03% | -0.33% | +56.49% | |
| 15 | MAZE | Maze Therapeutics Inc | Stock-Other | 1.78% | -0.33% | +3.45% | |
| 16 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.75% | -1.18% | -35.85% | |
| 17 | JBIO | Jade Biosciences Inc | Stock-Other | 1.69% | +0.48% | — | |
| 18 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.47% | -0.01% | — | |
| 19 | ✓ | Crescent Biopharma Inc. | Stock-Other | 1.46% | -0.30% | — | |
| 20 | ✓ | Zura Bio LTD | Stock-Other | 1.43% | -0.28% | +20.39% | |
| 21 | RLMD | Relmada Therapeutics Inc | Stock-Other | 1.26% | +0.18% | — | |
| 22 | ✓ | Engene Holdings Inc | Stock-Other | 1.21% | -1.21% | EXIT | |
| 23 | TENX | Tenax Therapeutics Inc | Stock-Other | 1.00% | -1.00% | EXIT | |
| 24 | ANL | Adlai Nortye Ltd-adr | Stock-Other | 0.83% | +0.29% | — | |
| 25 | IPSC | Century Therapeutics Inc | Stock-Other | 0.73% | -0.08% | — | |
| 26 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.73% | +0.03% | — | |
| 27 | HELP | Cybin Inc | Stock-Other | 0.69% | +0.08% | +0.30% | |
| 28 | SRZN | Surrozen Inc | Stock-Other | 0.69% | -0.19% | — | |
| 29 | SEPN | Septerna Inc | Stock-Other | 0.45% | -0.45% | EXIT | |
| 30 | KRRO | Korro Bio Inc | Stock-Other | 0.43% | -0.03% | — | |
| 31 | ANRO | Alto Neuroscience Inc | Stock-Other | 0.42% | -0.02% | — | |
| 32 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.39% | +0.21% | — | |
| 33 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 0.05% | +0.22% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca Inc | +6.6% | -8.26% | Trim |
| 2 | DNTH | Dianthus Therapeutics Inc | +1.7% | +18.00% | Add |
| 3 | ORKA | Oruka Therapeutics Inc | +1.4% | — | Unchanged |
| 4 | SYRE | Spyre Therapeutics Inc | +1% | — | Unchanged |
| 5 | VOR | Vor Biopharma Inc | +0.8% | +56.49% | Add |
| 6 | ✓ | Crescent Biopharma Inc. | +0.2% | — | Unchanged |
| 7 | ELVN | Enliven Therapeutics Inc | +0.1% | -46.49% | Trim |
| 8 | ✓ | Zura Bio LTD | +0.1% | +20.39% | Add |
| 9 | ARTV | Artiva Biotherapeutics Inc | +0.1% | — | Unchanged |
| 10 | CGEM | Cullinan Therapeutics Inc | 0% | — | Unchanged |
| 11 | SRZN | Surrozen Inc | 0% | — | Unchanged |
| 12 | ORIC | Oric Pharmaceuticals Inc | -0.3% | -23.90% | Trim |
| 13 | SEPN | Septerna Inc | -0.4% | -17.15% | Trim |
| 14 | 4XC1 | Kalvista Pharmaceuticals Inc | -0.5% | -3.78% | Trim |
| 15 | DYN | Dyne Therapeutics Inc | -0.6% | — | Unchanged |
| 16 | COGT | Cogent Biosciences Inc | -0.6% | — | Unchanged |
| 17 | JBIO | Jade Biosciences Inc | -0.8% | — | Unchanged |
| 18 | HELP | Cybin Inc | -0.9% | +0.30% | Add |
| 19 | ✓ | Engene Holdings Inc | -0.9% | — | Unchanged |
| 20 | OCUL | Ocular Therapeutix Inc | -1.1% | +41.44% | Add |
| 21 | SVRA | Savara Inc | -1.3% | — | Unchanged |
| 22 | MAZE | Maze Therapeutics Inc | -1.4% | +3.45% | Add |
| 23 | CTMX | Cytomx Therapeutics Inc | -1.5% | -35.85% | Trim |
| 24 | VRDN | Viridian Therapeutics Inc | -3.1% | — | Unchanged |
| 25 | APGE | Apogee Therapeutics Inc | -5% | — | Unchanged |
| 26 | DMRA | Damora Therapeutics Inc | — | NEW | New buy |
| 27 | RLMD | Relmada Therapeutics Inc | — | NEW | New buy |
| 28 | UPB | Upstream Bio Inc | — | EXIT | Sold out |
| 29 | TENX | Tenax Therapeutics Inc | — | NEW | New buy |
| 30 | ANL | Adlai Nortye Ltd-adr | — | NEW | New buy |
| 31 | IPSC | Century Therapeutics Inc | — | NEW | New buy |
| 32 | KRRO | Korro Bio Inc | — | NEW | New buy |
| 33 | ANRO | Alto Neuroscience Inc | — | NEW | New buy |
| 34 | XFOR | X4 Pharmaceuticals Inc | — | NEW | New buy |
| 35 | ✓ | Casi Pharmaceuticals Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Venrock Adviser, LLC reported a total U.S. public equity portfolio value of $3.3B across 33 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
DMRA
市值: $93.3M
Top Position Liquidated / Trimmed
UPB
前期市值: $31.7M
During Q1 2026, Venrock Adviser, LLC's top holdings by market value included APGE (26.7%)、ERAS (9.9%)、ORKA (7.6%). The largest single position, APGE, represented 26.7% of total portfolio value.
In Q1 2026, Venrock Adviser, LLC made 22 total portfolio adjustments, initiating 8 new buys, adding to 6 positions, trimming 6 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.